Unraveling antibiotic resistance mechanisms in Mycobacterium abscessus: the potential role of efflux pumps

Autor: Saskia E. Mudde, Jodie A. Schildkraut, Nicole C. Ammerman, Corné P. de Vogel, Jurriaan E.M. de Steenwinkel, Jakko van Ingen, Hannelore I. Bax

Publikováno v: Journal of Global Antimicrobial Resistance, Vol 31, Iss , Pp 345-352 (2022)

ABSTRACT: Objectives: Mycobacterium abscessus is an opportunistic respiratory pathogen in patients with underlying lung disease. It is infamously known for its low treatment success rates because of its resistance to multiple classes of antibiotics.

Externí odkaz: https://doaj.org/article/64f40b3ee8c649f5b13b24f9e90cc139

An Adaptive Biosystems Engineering Approach towards Modeling the Soluble-to-Insoluble Phase Transition of Clofazimine

Autor: Andrew R. Willmer, Steven Dunne, Rosemary Swanson, Deepak Almeida, Nicole C. Ammerman, Kathleen A. Stringer, Edmund V. Capparelli, Gus R. Rosania

Publikováno v: Pharmaceutics, Vol 14, Iss 1, p 17 (2021)

Clofazimine (CFZ) is a weakly basic, small-molecule antibiotic used for the treatment of mycobacterial infections including leprosy and multidrug-resistant tuberculosis. Upon prolonged oral administration, CFZ precipitates and accumulates within macr

Externí odkaz: https://doaj.org/article/8060cdf7bee147079522fc6df529c075

Shorter-course treatment for Mycobacterium ulcerans disease with high-dose rifamycins and clofazimine in a mouse model of Buruli ulcer.

Autor: Paul J Converse, Deepak V Almeida, Rokeya Tasneen, Vikram Saini, Sandeep Tyagi, Nicole C Ammerman, Si-Yang Li, Nicole M Anders, Michelle A Rudek, Jacques H Grosset, Eric L Nuermberger

Publikováno v: PLoS Neglected Tropical Diseases, Vol 12, Iss 8, p e0006728 (2018)

TRIAL REGISTRATION:ClinicalTrials.gov NCT03474198, NCT01659437.

Externí odkaz: https://doaj.org/article/65826f0602744e5eba53c6c5af40e358

Comparative efficacy of rifapentine alone and in combination with isoniazid for latent tuberculosis infection

Autor: Jacqueline P Ernest, Timothy R. Sterling, Rada M. Savic, Nan Zhang, Robert Belknap, Kendra K. Radtke, Nicole C. Ammerman, Rosanna Boyd, Eric L. Nuermberger

Publikováno v: Antimicrobial agents and chemotherapy, vol 65, iss 12
Antimicrobial Agents and Chemotherapy, 65(12):e01705-21. American Society for Microbiology
Antimicrob Agents Chemother

Rifapentine has facilitated treatment shortening for latent tuberculosis infection (LTBI) in combination with isoniazid once weekly for 3 months (3HP) or daily for 1 month (1HP). Our objective was to determine the optimal rifapentine dose for a 6-wee

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e434301e6c33ea51f6be00d78a9853b
https://doi.org/10.1128/AAC.01705-21

Spotted-Fever Group Rickettsia in Dermacentor variabilis, Maryland

Autor: Nicole C. Ammerman, Katherine I. Swanson, Jennifer M. Anderson, Timothy R. Schwartz, Eric C. Seaberg, Gregory E. Glass, Douglas E. Norris

Publikováno v: Emerging Infectious Diseases, Vol 10, Iss 8, Pp 1478-1481 (2004)

Three-hundred ninety-two adult Dermacentor variabilis were collected from six Maryland counties during the spring, summer, and fall of 2002. Infection prevalence for spotted fever group Rickettsia was 3.8%, as determined by polymerase chain reaction.

Externí odkaz: https://doaj.org/article/ce8d858c77fa4eb2a12c07a48c696021